Navigation Links
NCI Funded Clinical Trial to Study Treatment of Breast Cancer Using Cryoablation
Date:10/28/2008

Sanarus' Visica 2(TM) Treatment System Selected as Exclusive Cryoablation

Treatment Technology

PLEASANTON, Calif., Oct. 28 /PRNewswire/ -- The American College of Surgeons Oncology Group (ACOSOG) which just initiated a National Cancer Institute (NCI) funded clinical trial entitled, "A Phase II Trial Exploring the Success of Cryoablation Therapy in the Treatment of Invasive Breast Carcinoma," has selected the Visica 2(TM) Treatment System from Sanarus Medical as the exclusive technology to be utilized in the cryoablation portion of this study.

The ACOSOG study protocol (designated as Z1072) will evaluate not only cryoablation but also the ability of Magnetic Resonance Imaging (MRI) to evaluate post-cryoablation efficacy in approximately 100 patients and 20 clinical sites. Patient enrollment into the study is currently anticipated for early 2009. The Phase II Trial is similar to a pilot study conducted by Gary Levine, MD, Medical Director at Hoag Breast Care Center in Newport Beach, Calif., and Steven Poplack, MD, Co-Director of Breast Imaging at Dartmouth Hitchcock Medical Center. Results of the pilot study will be presented for the first time at this year's Radiological Society of North America (RSNA) 94th Scientific Assembly and Annual Meeting in Chicago. Both the pilot study and pending ACOSOG clinical trial share the common clinical protocol elements of cryoablation followed by MRI, surgical resection of the tumor and subsequent pathological evaluation.

"Cryoablation has been used effectively for years to treat a number of medical conditions, including benign breast tumors, so it is a natural progression to study its use in the treatment of breast cancer," said Dr Levine. "We are very encouraged about the promising initial results in our pilot study and believe further research is warranted in order to develop and refine this potential breakthrough breast cancer treatment."

Cryoablation is a minimally invasive non-surgical procedure that uses extreme cold to destroy tumors. The Sanarus Visica System has predominately been used in the cryoablation of non-cancerous tumors called fibroadenomas since its initial FDA market clearance in March of 2002. This office-based procedure, which usually takes less than 20 minutes, involves placing a small needle into the center of the tumor using ultrasound guidance and subsequently freezing and killing the tumor. The safety and efficacy of cryoablation have been well established in over 2,000 fibroadenomas that have been treated with the System to date.

"We are very pleased that ACOSOG chose cryoablation as the preferred thermal ablation modality over other ablation modalities such as radio- frequency (RF), interstitial laser, microwave, or focused ultrasound," said John F. Howe, President and Chief Executive Officer of Sanarus. "We are equally pleased that the award winning Sanarus Visica 2 Treatment System was selected as the preferred cryoablation system. This speaks volumes to the future potential of our System in expanded applications."

The Visica 2 System recently received national recognition with a Wall Street Journal Technology Innovation Award; and the Humanitarian Application of the Year Award from National Instruments.

The ACOSOG is one of 10 cooperative groups funded by the National Cancer Institute (NCI) to develop and coordinate multi-center clinical trials and is the only cooperative group whose primary focus is the surgical management of patients with malignant solid tumors. Additional information regarding the ACOSOG clinical trial is available to ACOSOG members via the organizations website http://www.ACOSOG.org under the heading of the Z1072 Clinical Protocol.

About Sanarus Medical

Sanarus Medical is based in Pleasanton, Calif., and is focused on providing patients and physicians with minimally invasive, office-based breast care management solutions from diagnosis to treatment. Using cryoablation technology, Sanarus has developed proprietary technologies to provide breast surgeons and radiologists with a comprehensive and minimally invasive way to diagnose and treat breast patients. The Sanarus technologies change the way that patients are managed, from an operating room-based, surgically intensive care pathway to a more comfortable, cost effective, office-based care pathway. The company's Website is http://www.sanarus.com.


'/>"/>
SOURCE Sanarus Medical
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Potential Breakthrough Cancer Treatment Emerges from MIPS-Funded Clinical Trial Teaming CSA Medical Inc. and University of Maryland Researchers
2. Premier Research Honored as Clinical Research Team of the Year at 2008 GCPj Awards
3. PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)
4. Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus
5. Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
6. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
7. Qualia Clinical Services Chooses ALPHADAS(R) for Phase I Clinical Trials
8. Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND
9. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
10. Multi-Centre European Clinical Trial Shows Advanced Dysplasia and Early Cancer of Esophagus Cured With Combined Endoscopic Resection and Radiofrequency Ablation With HALO Ablation System
11. CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 ... the "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural ... Structural electronics involves electronic and/or ... protective structures, replacing dumb structures such as vehicle ...
(Date:6/24/2016)... 2016 Research and Markets has announced ... Diagnostic Tests" report to their offering. ... The World Market for Companion Diagnostics covers ... Market analysis in the report includes the following: ... Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
Breaking Medicine News(10 mins):